The application of cold plasma therapy for the treatment of cancer is one promising field of study. This therapy can target and kill cancer cells while sparing healthy cells. The reactive oxygen species (ROS) and reactive nitrogen species (RNS), produced during plasma treatment is responsible for the cancer cells death. The research on cold plasma therapy is underway and has the potential to enhance current cancer treatments. Breast, lung, and skin cancer have all been treated with excellent success with cold plasma treatment. Cold plasma therapy has been shown to have anti-inflammatory, anti-angiogenic, and immunomodulatory properties in addition to its capacity to target cancer cells specifically, which may further increase its therapeutic potential. Additionally, it has been demonstrated that the efficiency of cold plasma therapy combined with other cancer therapies like chemotherapy, radiation therapy, and immunotherapy enhance the overall success of cancer treatment. Despite the positive outcomes of cold plasma treatment, additional studies are required to completely comprehend its mechanisms of action and improving its application in clinical settings. We entail further research on the ideal therapy variables, such as the kind of plasma used, the amount of energy given, the length of the procedure, and the creation of new, more effective plasma devices. In general, cold plasma therapy promises to revolutionize cancer treatment and prolong the lives of many cancer patients. The mechanisms of cold plasma treatment are examined in this review, along with its uses in oncology, including <i>in vitro</i> and<i> in vivo</i> investigations.